Novavax | NVAX - Gross Profit On Sales

Stock Price
8.70
Daily Change
0.28 3.33%
Monthly
6.23%
Yearly
6.23%
Q1 Forecast
8.43

Novavax reported $23.89M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
Adma Biologics USD 75.63M 8.4M Sep/2025
Agenus USD 23.93M 2.79M Mar/2025
AstraZeneca USD 12.39B 5M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 202.74M Dec/2024
Cassava Sciences USD -3.96M 1.16M Sep/2025
Geron USD 46.18M 1.66M Sep/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
MannKind USD 2.1M 216K Sep/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD 226M 583M Dec/2025
Novartis USD 10.82B 694M Sep/2025
Novavax USD 23.89M 239.21M Sep/2024
Pfizer USD 3.54B 7.61B Sep/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
TG Therapeutics USD 133.62M 11.41M Sep/2025